🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

NeurologyICD-10: G40

Find Recruiting Clinical Trials for Epilepsy

Search drug-resistant epilepsy, focal, generalized, and rare epilepsy syndrome trials — matched to your seizure type and prior AED history.

🔍 Search Epilepsy Trials →

About Epilepsy

Epilepsy affects approximately 50 million people worldwide and 3.4 million Americans, making it one of the most common neurological disorders. It is characterized by recurrent unprovoked seizures resulting from abnormal electrical activity in the brain. While approximately 70% of patients achieve seizure control with antiepileptic drugs (AEDs), 30% have drug-resistant epilepsy (DRE) — defined as failure of two appropriately chosen and tolerated AEDs. DRE represents the primary clinical unmet need and the focus of most epilepsy clinical trials.

What Types of Epilepsy Clinical Trials Exist?

Epilepsy trials target both broad-spectrum and syndrome-specific populations. Drug-resistant focal epilepsy trials test new AED mechanisms (AMPA receptor antagonists, selective Nav1.6 inhibitors, SV2A modulators), neuromodulation devices (RNS, DBS, VNS optimization), and dietary intervention studies. Genetic epilepsy trials (Dravet syndrome/SCN1A, Lennox-Gastaut, tuberous sclerosis) test precision medicine approaches including antisense oligonucleotides and gene therapy. Seizure frequency (monthly), seizure type (focal, generalized), prior AED failures, and epilepsy syndrome determine eligibility.

Find Recruiting Epilepsy Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Epilepsy Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for epilepsy?▾
Recruiting epilepsy trials include new AEDs (Nav channel subtype-selective inhibitors, AMPA antagonists), neuromodulation device trials (RNS, DBS), dietary ketogenic therapy optimization, cannabidiol and cannabinoid studies, genetic/rare epilepsy syndrome-specific trials (Dravet syndrome, TSC, CDKL5), and seizure detection and prediction device studies.
What is drug-resistant epilepsy and am I eligible for trials?▾
Drug-resistant epilepsy (DRE) is defined as failure to achieve sustained seizure freedom with two appropriately chosen, tolerated, and adequately dosed AED trials. This affects approximately 30% of epilepsy patients. Most advanced AED and neuromodulation trials specifically require documented DRE — at least 2 (often 3) prior AED failures — to enroll.
Does my epilepsy type or syndrome affect trial eligibility?▾
Yes significantly. Focal epilepsy trials differ from generalized epilepsy trials. Rare genetic epilepsy syndromes (Dravet syndrome, Lennox-Gastaut, CDKL5, Angelman) have dedicated syndrome-specific trials. Some trials require specific EEG findings, MRI lesion characteristics (cortical dysplasia, hippocampal sclerosis), or genetic testing results (SCN1A, TSC1/2 mutations).

Related Conditions

Parkinson's DiseaseALSMigraine

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.